Johnson&Johnson CEO Joaquin Duato stated at the company's Investor Day event on December 5th that the company currently has no plans to produce weight loss pills due to the intense competition in the market.
Du Anqing stated that Johnson&Johnson is focusing on expanding widely in fields such as neurology and oncology. Du Anqing said, "If Johnson&Johnson has the opportunity to stand out in the weight loss drug market through assets that complement the company's business, it may reconsider."